

**Information for Pharmacists**

**Claims Submission Procedure –  
Prazosin 1mg, 2mg, 5mg Capsules**

**Effective October 28, 2023  
Updated November 7, 2023**

Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.

**\*\*Pharmacies do NOT receive drug interaction information when submitting claims using PINs. Please review all claims carefully prior to submitting\*\***

- There is variable supply of the following products:

Brand	DIN	Drug/Format
Apotex	00882801	Prazosin 1mg
	00882828	Prazosin 2mg
	00882836	Prazosin 5mg
Teva	01934198	Prazosin 1mg
	01934201	Prazosin 2mg
	01934228	Prazosin 5mg

- Due to this shortage, Manitoba is outlining the following product selection tree. This selection tree is to encourage pharmacy providers to use existing commercial supply while outlining an alternative option if supply is unavailable:
  - Commercially available product should be dispensed if the pharmacy has inventory on hand or can obtain product through normal distribution channels;
  - The pharmacy vendor may obtain commercially available product from another provider (e.g. another member within the same chain);
  - If Canadian labeled product cannot be obtained, then the US-labelled Prazosin capsules should be dispensed.
- The following PINs should be used when submitting claims for US labelled Prazosin capsules:

PIN	Drug	Format
00912004	US-labeled Prazosin Capsules	1mg
00912005	US-labeled Prazosin Capsules	2mg
00912006	US-labeled Prazosin Capsules	5mg

- Manitoba will inform pharmacy providers once the shortage has been resolved and the PIN is no longer required and has been withdrawn for coverage.

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at:

<https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to [NIBDrugShortages@gov.mb.ca](mailto:NIBDrugShortages@gov.mb.ca).